Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 49

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 49
---
 may incur to develop, commercialize or acquire additional      
 products and technologies or for other purposes, such as the expansion of our sales team and our facilities; |

| ● | changes in governmental funding of life sciences research and development or changes that impact budgets 
 or budget cycles;                                                                                        |

| ● | the timing of when we recognize any revenues; |

| ● | future accounting pronouncements or changes in our accounting policies; |

| ● | the outcome of any future litigation or governmental investigations involving the Company, our industry 
 or both;                                                                                                |

| ● | higher than anticipated service, replacement and warranty costs; |

| ● | the impact of the COVID-19 pandemic on the economy, investment in the life sciences and medical technology                                   
 industries, our business operations, and resources and operations of our suppliers, future distributors and current and potential customers; |

| ● | the impact of political instability and military conflict, such as the conflict in Ukraine, which has                                 
 resulted in instability in the global financial markets and export controls, and which could result in supply disruptions for us; and |

| ● | general industry, economic and market conditions and other factors, including factors unrelated to our 
 operating performances or the operating performance of our competitors.                                |

The cumulative effects of the
factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a period-to-period basis may not be meaningful.

This variability and unpredictability
could also result in us failing to meet the expectations of industry or financial analysts or investors for any period. If we are unable
to further commercialize products or generate revenue, or if our operating results fall below the expectations of analysts or investors
or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the market price
of our common stock could decline.

<div align='center'>26</div>

If our financial performance fails to meet the expectations of investors and public market analysts, the market price of our common stock could decline.

Our revenues and operating
results may fluctuate significantly from quarter to quarter. We believe that period-to-period comparisons of our operating results may
not be meaningful and should not be relied on as an indication of our future performance. If quarterly revenues or operating results fall
below the expectations of investors or public market analysts, the trading price of our common stock could decline substantially. Factors
that might cause quarterly fluctuations in our operating results include:

| ● | our inability